Pulmatrix Inc (NASDAQ: PULM) is having a great start to the trading session this morning, and for good reason. The company announced the publication of data from a Phase 1 clinical trial. Of course, the data was positive, leading to excitement among investors and sending the stock screaming for the top. Today, we’ll talk about:
- The data;
- what we’re seeing from PULM;
- and what we’ll be watching for with regard to the stock ahead.
PULM Heads For The Top On Phase 1 Data Publication
As mentioned above, Pulmatrix is having an incredibly strong start to the trading session this morning after the company announced that Phase 1 clinical data has been published. In a press release issued early this morning, teh company announced the publication of data from a dose-ranging Phase 1 clinical study. In the study, the company assessed PUR-200 as a treatment for COPD patients. In the release, PULM said that data from the study was published online in the Brinish Journal of Clinical Pharmacology.
PUR0200 is a drug that combines tiotropium bromide with the iSPERSE™ drug delivery platform designed by PULM. Using salt based excipients and spray drying to create particles for inhallation that are intended to improve the delivery of drugs to the lungs compared to lactos-blend dry powders, the drug delivery platform is generating overwhelmingly positive results. In fact, in the Phase 1 trial, PUR0200 treatment at all doses resulted in a statistically significant increase in FEV1 compared to placebo and caused similar bronchodilation compared to Spiriva HandiHaler. In a statement, David Hava, Ph.D., Chief Scientific Officer at PULM, had the following to offer:
The results from this Phase 1 clinical study of PUR0200 are the first clinical demonstration of the delivery advantages of the Pulmatrix iSPERSE technology compared to lactose-based dry powder inhalers… The ability to achieve similar lung deposition and clinical improvement at reduced exposure to patients highlights the potential of iSPERSE to enable differentiated versions of existing products and to enable new products for the treatment of respiratory disease.
What We’re Seeing From The Stock
One of the first lessons that we learn when we start to work in the market is that the news causes moves. In the case of Pulmatrix, the news proved to be overwhelmingly positive. After all, in the clinical phase biotechnology game, there are few pieces of news that can move the market quite like news surrounding positive data. So, it’s no surprise that excited investors are sending the stock screaming for the top. Of course, our partners at Trade Ideas were the first to alert us to the gains. Currently (11:19), PULM is trading at $0.58 per share after a gain of $0.025 per share or 4.51% thus far today.
Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!
What We’ll Be Watching For Ahead
Moving forward, the CNA Finance team will continue to keep a close eye on PULM. In particular, we’re interested in following the ongoing work surrounding PUR0200 as the treatment seems to be yielding overwhelmingly positive results. Nonetheless, we’ll continue to follow the sotry closely and bring the news to you as it breaks!